Affiliation:
1. Department of Pharmaceutical Chemistry, College of Pharmacy University of Basrah Basrah Iraq
2. Department of Pharmacology and Toxicology, College of Pharmacy University of Basrah Basrah Iraq
3. Department of Pharmaceutical Chemistry, College of Pharmacy University of Baghdad Baghdad Iraq
4. Department of Biology and Biotechnology, Faculty of Science The Hashemite University Zarqa Jordan
5. Department of Biochemistry and Molecular Biology, College of Natural Sciences Colorado State University Fort Collins Colorado USA
6. Department of Basic Dental Sciences, Faculty of Dentistry The Hashemite University Zarqa Jordan
Abstract
AbstractThe close association between inflammation and cancer inspired the synthesis of a series of 1,3,4‐oxadiazole derivatives (compounds H4‐A‐F) of 6‐methoxynaphtalene. The chemical structures of the new compounds were validated utilizing Fourier‐transform infrared, proton nuclear magnetic resonance, and carbon‐13 nuclear magnetic resonance spectroscopic techniques and CHN analysis. Computer‐aided drug design methods were used to predict the compounds biological target, ADMET properties, toxicity, and to evaluate the molecular similarities between the design compounds and erlotinib, a standard epidermal growth factor receptor (EGFR) inhibitor. The antiproliferative effects of the new compounds were evaluated by the 3‐(4,5‐dimethyl‐2‐thiazolyl)‐2,5‐diphenyl‐2H‐tetrazolium bromide assay, cell cycle analysis, apoptosis detection by microscopy, quantitative reverse transcription‐polymerase chain reaction, and immunoblotting, and EGFR enzyme inhibition assay. In silico analysis of the new oxadiazole derivatives indicated that these compounds target EGFR, and that compounds H4‐A, H4‐B, H4‐C, and H4‐E show similar molecular properties to erlotinib. Additionally, the results indicated that none of the synthesized compounds are carcinogenic, and that compounds H4‐A, H4‐C, and H4‐F are nontoxic. Compound H4‐A showed the best‐fit score against EGFR pharmacophore model, however, the in vitro studies indicated that compound H4‐C was the most cytotoxic. Compound H4‐C caused cytotoxicity in HCT‐116 colorectal cancer cells by inducing both apoptosis and necrosis. Furthermore, compounds H4‐D, H4‐C, and H4‐B had potent inhibitory effect on EGFR tyrosine kinase that was comparable to erlotinib. The findings of this inquiry offer a basis for further investigation into the differences between the synthesized compounds and erlotinib. However, additional testing will be needed to assess all of these differences and to identify the most promising compound for further research.